Next Article in Journal
3-(tert-Butyl)-N-(4-methoxybenzyl)-1-methyl-1H-pyrazol-5-amine
Previous Article in Journal
Synthesis of 1,5-Disubstituted Tetrazoles in Aqueous Micelles at Room Temperature
Open AccessShort Note

(E)-4-(3-(3-(4-Methoxyphenyl)acryloyl)phenoxy)butyl 2-Hydroxybenzoate

1
Department of Pharmacy, Sekolah Tinggi Ilmu Farmasi (STIFAR) Riau, Pekanbaru 28293, Indonesia
2
Department of Biomedical Engineering, Faculty of Engineering, King Mongkut’s Institute of Technology Ladkrabang, Bangkok 10520, Thailand
3
Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Riau, Pekanbaru 28293, Indonesia
*
Author to whom correspondence should be addressed.
Molbank 2021, 2021(1), M1195; https://doi.org/10.3390/M1195
Received: 22 February 2021 / Revised: 1 March 2021 / Accepted: 2 March 2021 / Published: 9 March 2021
(This article belongs to the Section Organic Synthesis)
A new hybrid compound of chalcone-salicylate (title compound) has been successfully synthesized using a linker mode approach under reflux condition. The structure of the title compound has been established by spectroscopic analysis including UV-Vis, FT-IR, HRMS, 1D, and 2D NMR. Then, computational approach was also applied in this study through molecular docking and MD simulation to explore its potency against breast cancer. The results of the molecular docking study showed that the title compound exhibited more negative value of binding free energy (−8.15 kcal/mol) than tamoxifen (−7.00 kcal/mol). In addition, no striking change in the positioning of the interacting residues was recorded before and after the MD simulations. Based on the studies, it can be predicted that the title compound has a cytotoxic activity potency against breast cancer through ERα inhibition and it presumably can be developed as anticancer agent candidate. View Full-Text
Keywords: chalcone; salicylic acid; hybrid compound; molecular hybridization; chalcone-salicylate; in silico study; computational approaches; molecular docking; MD simulation chalcone; salicylic acid; hybrid compound; molecular hybridization; chalcone-salicylate; in silico study; computational approaches; molecular docking; MD simulation
Show Figures

Graphical abstract

MDPI and ACS Style

Ikhtiarudin, I.; Dona, R.; Frimayanti, N.; Utami, R.; Susanti, E.; Mentari, M.; Nurmaida, N.; Agistia, N.; Herfindo, N.; Zamri, A. (E)-4-(3-(3-(4-Methoxyphenyl)acryloyl)phenoxy)butyl 2-Hydroxybenzoate. Molbank 2021, 2021, M1195. https://doi.org/10.3390/M1195

AMA Style

Ikhtiarudin I, Dona R, Frimayanti N, Utami R, Susanti E, Mentari M, Nurmaida N, Agistia N, Herfindo N, Zamri A. (E)-4-(3-(3-(4-Methoxyphenyl)acryloyl)phenoxy)butyl 2-Hydroxybenzoate. Molbank. 2021; 2021(1):M1195. https://doi.org/10.3390/M1195

Chicago/Turabian Style

Ikhtiarudin, Ihsan; Dona, Rahma; Frimayanti, Neni; Utami, Rahayu; Susanti, Emma; Mentari, Mentari; Nurmaida, Nurmaida; Agistia, Nesa; Herfindo, Noval; Zamri, Adel. 2021. "(E)-4-(3-(3-(4-Methoxyphenyl)acryloyl)phenoxy)butyl 2-Hydroxybenzoate" Molbank 2021, no. 1: M1195. https://doi.org/10.3390/M1195

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop